News ImmuneRegen NewsImmuneRegen BioSciences Responds to Department of DefensePacific Northwest National Laboratory Collaborates with ImmuneRegen to Propose Universal Protectant Study SCOTTSDALE, Ariz., Jan. 17 /PRNewswire-FirstCall/ -- Research and development biotechnology company ImmuneRegen BioSciences, Inc. a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), today announced it has recently submitted the requested proposal to the Department of Defense (DoD) for the 2006 Medical Science And Technology (S&T) Chemical And Biological Defense Transformational Medical Technologies Initiative (TMTI). ImmuneRegen has submitted for this grant in collaboration with Pacific Northwest National Laboratory. The submission makes a case for the development of Homspera(TM), a proprietary compound, as a Universal Protectant based on a Common Pathogenic Pathway. "We are encouraged by Pacific Northwest National Laboratory's support in our proposal," says ImmuneRegen CEO Michael Wilhelm. "We believe their unique experience and expertise in the areas of chemical, biological and radiological threats will enhance our research and directly address the objectives of public health and national security. The proposal is further validated by the international recognition of the excellence of the NIH-supported proteomics program at Pacific Northwest National Laboratory (PNNL)." The collaboration with PNNL will enable ImmuneRegen to perform more in-depth studies on Homspera than were previously unavailable. Homspera is the name for ImmuneRegen's synthetic Substance P analog, Sar(9), Met (O2)(11)-Substance P. Substance P is a naturally occurring neuropeptide that can be found throughout the body, including in the nerves surrounding the airways of humans and several other species. ImmuneRegen's proposal references several past biological studies of Homspera including radiation studies, formalin exposure studies and viral studies, including exposure of experimental animals to Hong Kong influenza virus. Past testing of Homspera has shown a 50% survival rate among irradiated mice (7.75 gray) treated Post Lethal Exposure (PLE). Additionally, ImmuneRegen researchers have found that Homspera preserves pulmonary structure and function after toxicant exposure and impacts immunomodulatory responses following respiratory virus exposure, decreasing morbidity and mortality in experimental animals. About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|